Brief: T2 Biosystems Receives FDA Breakthrough Device Designation For Candida Auris Diagnostic Test
20/07/2023 14:17
July 20 (Reuters) - T2 Biosystems Inc TTOO.O :
* T2 BIOSYSTEMS RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION
FOR
CANDIDA AURIS DIAGNOSTIC TEST
Source text for Eikon: ID:nGNX407NHZ
Further company coverage: TTOO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on T2 Biosystems
See all newsBrief: T2 Biosystems Announces Intent To Wind Down Operations
Brief: T2 Biosystems Enters Amendment No. 12 To Term Loan Agreement
Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
T2 Biosystems Inc reports results for the quarter ended in June - Earnings Summary
Brief: T2 Biosystems Announces Commercial Expansion Through Malaysia And Indonesia Distributor